Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line

Biochem Pharmacol. 2009 Jul 1;78(1):21-32. doi: 10.1016/j.bcp.2009.03.013. Epub 2009 Mar 24.

Abstract

Many tumors are resistant to drug-induced cell-cycle arrest and apoptosis. We have reported that apoptosis can be restored in human multidrug-resistant (MDR) hepatocellular carcinoma cell lines by celecoxib. Here we show that P-glycoprotein (P-gp) mediates cell-cycle arrest and autophagy induced by celecoxib in human MDR overexpressing hepatocellular carcinoma cell line by down-regulation of the HGF/MET autocrine loop and Bcl-2 expression. Exposure of cells to a low concentration of celecoxib down-regulated the expression of mTOR and caused G1 arrest and autophagy, while higher concentration triggered apoptosis. Cell growth inhibition and autophagy were associated with up-regulation of the expression of TGFbeta1, p16(INK4b), p21(Cip1) and p27(Kip1) and down-regulation of cyclin D1, cyclin E, pRb and E2F. The role of P-glycoprotein expression in resistance of MDR cell clone to cell-cycle arrest, autophagy and apoptosis was shown in cells transfected with MDR1 small interfering RNA. These findings demonstrate that the constitutive expression of P-gp is involved in the HGF/MET autocrine loop that leads to increased expression of Bcl-2 and mTor, inhibition of eIF2alpha expression, resistance to autophagy/apoptosis and progression in the cell-cycle. Since mTor inhibitors have been proposed in treatment of "drug resistant" cancer, these data may help explain the reversing effect of mTor inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / physiology
  • Apoptosis
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / enzymology
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / pathology
  • Celecoxib
  • Cell Cycle / drug effects
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cyclin D1 / genetics
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Cyclin-Dependent Kinase Inhibitor p27 / genetics
  • Cyclooxygenase Inhibitors / pharmacology
  • Drug Resistance, Multiple
  • G1 Phase
  • Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) / genetics
  • Hepatocyte Growth Factor / genetics*
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / enzymology
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / pathology
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Pyrazoles / pharmacology
  • RNA, Neoplasm / genetics
  • RNA, Small Interfering / genetics
  • Sulfonamides / pharmacology

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclooxygenase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Pyrazoles
  • RNA, Neoplasm
  • RNA, Small Interfering
  • Sulfonamides
  • Cyclin D1
  • Cyclin-Dependent Kinase Inhibitor p27
  • Hepatocyte Growth Factor
  • Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)
  • Celecoxib